Cargando…
1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?
BACKGROUND: Patients who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT) are at increased risk for invasive fungal infections with associated high morbidity and mortality that necessitates the use of prophylactic antifungals. Voriconazole is commonly used for prophylaxis, but t...
Autores principales: | Hadjivassiliou, Giorgos, Rummage, Claire, Hoesley, Craig, Brown, Matthew L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809616/ http://dx.doi.org/10.1093/ofid/ofz360.1596 |
Ejemplares similares
-
Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis
por: Agrawal, Vaibhav, et al.
Publicado: (2020) -
1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020) -
Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017) -
Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?
por: Honore, Patrick M, et al.
Publicado: (2015) -
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)